ThioBridge™ next-generation conjugation technology
ThioBridge™ conjugation technology has been proven to enhance ADC development by overcoming issues with existing technologies in order to improve stability, potency, and efficacy.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Abzena's unique ThioBridge™ platform is truly next-generation conjugation technology. It overcomes some of the shortcomings of first-generation conjugation technologies, by using site-specific conjugation to antibody interchain disulfide. It offers a more uniform DAR profile and stable attachment compared to maleimide conjugation and allows for PK profiles to be optimized with architectural design flexibility when it comes to the payload and spacer.
ThioBridge Advantages:
Site-specific attachment at the interchain disulfides
- Ag+ binding
- Homogeneous DAR
- Stable linker
Modulate Binding to Fc receptors
- Lower FcyR binding
- Intact FcRn binding
- Versatile
All payload classes, and architectural design for DAR optimization.
Understanding the complex landscape of bioconjugates
Bioconjugates are a rapidly expanding therapeutic modality demonstrating tremendous benefit for cancer patients already, and with significant promise in inflammatory, infectious and rare diseases. Key to the successful development of bioconjugates is the selection of an appropriate conjugation strategy.
In this eBook, Dr. Nicolas Camper, Vice President, and Dr. Petra Dieterich, Senior Vice President & Scientific Leader, Abzena, review and discuss the main categories of therapeutic bioconjugates, focusing on their key required characteristics or target product profile (TPP). Including, key considerations for selecting the most appropriate conjugation strategy for each application and insights into technological options along with real-world examples of bioconjugates in clinical development and in-market.
Download this SelectScience guide to explore how to:
- Understand the major categories of therapeutic bioconjugates
- Identify the essential characteristics that define a strong target product profile (TPP) for bioconjugate therapeutics, and why these attributes guide development success
- Learn how to select the most appropriate conjugation strategy for a given therapeutic goal, considering stability, efficacy, and manufacturability.
- Uncover current technological options and real‑world examples of bioconjugates in clinical development and on the market.
Resource details:
- Document type: SelectScience guide
- Page count: 25
- Read time: 37.5 mins
